In pediatric high-grade gliomas, hypermutator and PXA-like tumors exhibit significant CD8+ T cell infiltration and associated improved survival with bevacizumab treatment, whereas histone H3-mutant tumors remain largely immune cold and are non-responsive to bevacizumab [49]. Here, CD8A is linked to central nervous system cancer.